Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
MAR-Trientine Trientine Hydrochloride Wilson's Disease Reimburse with clinical criteria and/or conditions Complete
Mavenclad cladribine Multiple Sclerosis, relapsing-remitting Reimburse with clinical criteria and/or conditions Complete
Maviret glecaprevir / pibrentasvir Hepatitis C, chronic Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Maviret glecaprevir pibrentasvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Mayzent siponimod Secondary progressive multiple sclerosis Reimburse with clinical criteria and/or conditions Complete
MDK-Nitisinone nitisinone Hereditary tyrosinemia type 1 Reimburse with clinical criteria and/or conditions Complete
Mekinist Trametinib Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Mictoryl Propiverine hydrochloride Overactive bladder (OAB) Reimburse with clinical criteria and/or conditions Complete
Mifegymiso Mifepristone and misoprostol Medical termination of pregnancy (gestational age up to 49 days) Reimburse Complete
Mifegymiso Mifepristone and misoprostol Medical termination of pregnancy (gestational age up to 49 days) Withdrawn